Skip to main content
. 2017 Jun 23;7:4214. doi: 10.1038/s41598-017-04086-w

Figure 3.

Figure 3

MicroRNA-134 (miR-134) targets IL-18 binding protein (IL-18BP). (a) The potential target for miR-134 was IL-18BP. Sequence alignment of miR-134 with reverse complementary IL-18BP (http://www.microrna.org). (b) 293 T cells were co-transfected with IL-18BP 3′UTR wild type (WT), IL-18BP 3′UTR mutant or empty pMIR-REPORT vector and pTK-RL plasmid, together with miR-134 mimic/mimic control or miR-134 inhibitor/inhibitor control. After 36 h, luciferase activities were measured and normalized by Renilla luciferase activity. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01. NS, non-statistical significant. Comparison of supernatant levels of IL-18BP (c) or IL-18 (d) released in THP-1 cells transfected with miR-134 mimic, miR-134 inhibitor, mimic/inhibitor control, or non-transfection cells (mock). Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, versus miR-134 inhibitor, mimic/inhibitor control, or non-transfection cells (mock), determined by the Student’s t-test.